The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus

DOI Web Site 2 Citations
  • Wenjuan Dong
    Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
  • Heather Mead
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Lei Tian
    Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
  • Jun-Gyu Park
    Disease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA
  • Juan I. Garcia
    Disease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA
  • Sierra Jaramillo
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Tasha Barr
    Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
  • Daniel S. Kollath
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Vanessa K. Coyne
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Nathan E. Stone
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Ashley Jones
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Jianying Zhang
    Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California, USA
  • Aimin Li
    Pathology Core, Shared Resources, Beckman Research Institute, City of Hope National Medical Center, Duarte, California, USA
  • Li-Shu Wang
    Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
  • Martha Milanes-Yearsley
    Department of Pathology, The Ohio State University, Columbus, Ohio, USA
  • Jordi B. Torrelles
    Disease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA
  • Luis Martinez-Sobrido
    Disease Intervention and Prevention, and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA
  • Paul S. Keim
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Bridget Marie Barker
    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA
  • Michael A. Caligiuri
    Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
  • Jianhua Yu
    Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California, USA
  • Tom Gallagher
    editor

Description

<jats:p>The pandemic of coronavirus disease 2019 (COVID-19) has reached nearly 240 million cases, caused nearly 5 million deaths worldwide as of October 2021, and has raised an urgent need for the development of novel drugs and therapeutics to prevent the spread and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To achieve this goal, an animal model that recapitulates the features of human COVID-19 disease progress and pathogenesis is greatly needed.</jats:p>

Journal

  • Journal of Virology

    Journal of Virology 96 (1), e0096421-, 2022-01-12

    American Society for Microbiology

Citations (2)*help

See more

Details 詳細情報について

Report a problem

Back to top